Search
forLearn
5 / 801 resultslearn Zinc Tri- Amino Acid complex
learn thiamin
learn copper tripeptide-1
learn threonine
Research
5 / 659 results
research Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome
Women with PCOS have higher levels of certain blood clotting factors, suggesting a greater risk of cardiovascular issues.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
People with alopecia areata may have a higher risk of blood clots.
research COVID-19 and Sex Differences
Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.
research Accelerated Wound Healing Using Nanoparticles
Nanoparticles can speed up wound healing and deliver drugs effectively but may have potential toxicity risks.
research Seaweeds as Source of Bioactive Substances and Skin Care Therapy—Cosmeceuticals, Algotheraphy, and Thalassotherapy
Seaweeds have beneficial compounds for skin care, including anti-aging and protective effects.
Community Join
5 / 1000+ resultscommunity GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Twist1 Group Buy: Yes it’s that easy
A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.